Duvyzat (givinostat): interim advice on risk mitigation measures

Drug Safety Update: Duvyzat (givinostat) interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat.

Published: 5 November 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has pubsliehd a drug safety update regarding Duvyzat (givinostat).

There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA has proposed updates to the product information. Interim monitoring advice is being provided by the MHRA based on these proposals, pending independent review and finalisation of the MHRA’s position.

Further information and advice can be found on the MHRA website.